COVID-19 oral drug significantly reduces infection mortality in the elderly
- The first Alzheimer’s disease Aβ and Tau pathological surrounding cell structure and gene expression map
- Magic TCR-T cell therapy: 72% of tumor lesions disappeared
- Monkeypox mRNA Vaccine Competition: U.S. vs. China
- Can an universal mRNA flu vaccine be against all 20 virus subtypes?
- Harvard found why high-protein diet improves sleep quality
- Will cancer vaccines be the direction of curing cancer?
COVID-19 oral drug significantly reduces infection mortality in the elderly
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- COVID-19 has been confirmed to cause DNA damage and cellular aging
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
The Lancet: COVID-19 oral drug significantly reduces infection mortality in the elderly.
On October 8, The Lancet published an article “Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study”, which is the largest real-world study on the effectiveness of two COVID-19 oral drugs in the treatment of Omicron variant strain infection.
Source: DOI: https://doi.org/10.1016/S0140-6736(22)01586-0
The research data comes from 1,074,856 community-infected patients in Hong Kong in 2022.
After screening, 4,983 molnupiravir users and 5,542 Paxlovid users were included in the statistics, of which 9,176 were older than 60 years old (87.1%) and completed the full course of vaccination. of only 2,650 (22.4%) .
That is to say, most of them belong to the high-risk group of COVID-19 infection – advanced age and unvaccinated.
The study found that the use of two COVID-19 drugs in the early stage of infection can significantly reduce the risk of disease progression and death in the elderly. Among them, the COVID-19 oral drug Paxlovid reduced the risk of death after hospitalization in the elderly by 79%.
Source: DOI: https://doi.org/10.1016/S0140-6736(22)01586-0
(source:internet, reference only)
Disclaimer of medicaltrend.org
